 |
 |
 |
||||||
 |
||||||||
 |
 |
 |
 |
|||||
 |
|
|
|
|||||
|
|
|
|
|
|
|
|
|
 |
 |
|
| Our
mission is to develop our ZFP TF gene regulation and ZFN gene modification technology as a new
class of human therapeutics. Our powerful technology can also be applied
in a variety of applications to enable therapeutic product
development. We are using Enabling Technology Agreements in these
areas to provide near term revenue. These agreements are typically
non-exclusive.
|
||
|
|
|
Partnerships are very important to us.
We are taking our first therapeutic programs
forward through early clinical trials but aim to develop these programs further with partners who provide funding or access to complementary technologies
such as delivery methods.
Collaborations in Enabling Technologies
Our Enabling Technology Agreements allow us to leverage our technology
and provide near to mid term revenue.
Opportunities:
- ZFP TF- and ZFN-Engineered Cell Lines for the Manufacturing
of Protein Pharmaceuticals.
We have an agreement with Medarex who is providing research funding, milestone payments and potentially royalties on sales of antibodies and protein pharmaceuticals manufactured using this technology. We have an agreement to provide ZFN-engineered cell lines to Pfizer Inc who provide research funding. We also have agreements with several other companies including Novo Nordisk, Novartis, Amgen and Kirin Brewery Company who are evaluating our ZFP TF and ZFN technology. - ZFP TFs for the Development of Therapeutics
Sangamo has also provided companies such as LifeScan, a Johnson & Johnson company, with ZFP TFs to aid in the development of new therapeutic treatments for diabetes in the emerging field of regenerative medicine.
.
back to top
|
Contact |  |
Careers | |
Site Map | |
Legal | |
Glossary |
|
|
|
|
|
|
|
|